[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350141-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350141-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","harnessing-tumor-organoids-to-revolutionize-immunotherapy-research","Harnessing Tumor Organoids to Revolutionize Immunotherapy Research","","Immunotherapy has emerged as a revolutionary approach to cancer treatment, yet the lack of robust preclinical testing platforms impedes progress in this field. Tumor organoids, three-dimensional structures derived from patient-specific samples, differ from conventional models by faithfully recapitulating the histological, genetic, and phenotypic characteristics of native tumors. Complex organoid models can partially recapitulate the tumor microenvironment by integrating immune cells, vascular-associated components, and cancer-associated fibroblasts.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/harnessing-tumor-organoids-to-revolutionize-immunotherapy-research/350141/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/harnessing-tumor-organoids-to-revolutionize-immunotherapy-research/350141.png","ImageObject",300,407,{"name":42,"@type":43},"Jordan Avery","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are preclinical testing platforms important for immunotherapy research?","Question",{"text":63,"@type":64},"Robust preclinical platforms are needed because immunotherapy progress is slowed by limitations in accurately evaluating treatments before clinical use.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What advantages do tumor organoids offer compared with conventional models?",{"text":68,"@type":64},"Tumor organoids better reflect histological, genetic, and phenotypic features of native tumors and can partially model the tumor microenvironment.",{"name":70,"@type":61,"acceptedAnswer":71},"How can organoid models incorporate tumor microenvironment components?",{"text":72,"@type":64},"By integrating immune cells, vascular-associated components, and cancer-associated fibroblasts, complex organoid systems can recapitulate aspects of the tumor microenvironment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350141,1790193645,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Cancer Medicine  \n|  REVIEW  OPEN ACCESS \u003Cbr>Harnessing Tumor Organoids to Revolutionize Immunotherapy Research\u003Cbr>Zhen Wang1,2  | Peipei Yin3 | Shizhan Cui1,4 | Hui Liu1 | Dan Li1 | Yang Yu1,5 | Baoshan Cao2 | Xiaojuan Liu1,2\u003Cbr>1Clinical Stem Cell Research Center, Peking University Third Hospital, Beijing, China | 2Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China | 3Depatment of Neurology, The 82nd Group Army Hospital of PLA, Baoding, China | 4College of Life Science\u003Cbr>and Technology, Beijing University of Chemical Technology, Beijing, China | 5Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu, China Correspondence: Baoshan Cao ([caobaoshan0711@aliyun.com](caobaoshan0711@aliyun.com)) | Xiaojuan Liu ([liuxiaojuanhk@gmail.com](liuxiaojuanhk@gmail.com))\u003Cbr>Received: 10 September 2025 | Revised: 9 March 2026 | Accepted: 17 March 2026\u003Cbr>Keywords: immunotherapy | organoids | tumor microenvironment |  |\n| --- | --- |\n| ABSTRACT\u003Cbr>Immunotherapy has emerged as a revolutionary approach to cancer treatment, yet the lack of robust preclinical testing platforms impedes progress in this field. Tumor organoids, three-dimensional structures derived from patient-specific samples, differ from conventional models by faithfully recapitulating the histological, genetic, and phenotypic characteristics of native tumors. Moreover, complex organoid models can partially recapitulate aspects of the tumor microenvironment through the integration of immune cells, vascular-associated components, and cancer-associated fibroblasts. This review systematically examines current methodologies for constructing TME-simulating organoids, along with their applications and future challenges in immunotherapy research, including immune checkpoint inhibitors, cell immunotherapy, bispecific antibodies, oncolytic viruses, and cancer vaccines. By elucidating the advantages and limitations of organoid technology in immunotherapy studies, this review exploresits potential to establish a novel platform for predictive evaluation of immunotherapy efficacy. Ultimately, it aims to provide innovative perspectives for future research directions in this field and contribute to enhancing therapeutic outcomes for cancer patients. |  |\n| 1 | Introduction | more effectively. Owing to its transformative clinical impact, immunotherapy was named the Breakthrough of the Year in |\n| Cancer remains a major global health burden with rising inci- | 2013 by Science, and the discovery of immune checkpoint in- |\n| dence. According to data from the World Health Organization, | hibitors such as CTLA-4 and PD-1 has been widely recognized |\n| approximately 20 million new cases and 9.7 million deaths | with the Nobel Prize in Physiology or Medicine in 2018 [2, 3] |\n| were reported in 2022, and incidence is projected to exceed | However, there are challenges in translating immunotherapy |\n| 35 million annually by 2050 [1] . Current cancer treatments, | from preclinical studies to clinical applications, with one of |\n| including surgery, chemotherapy, radiotherapy, and molecu- | the foremost challenges being the development of preclinical models that can accurately simulate human immunity [4] |\n| lar targeted therapy, have improved outcomes in selected pa- |  |\n| tients but remain limited by invasiveness, systemic toxicity, | The tumor microenvironment (TME), shaped by genomic |\n| resistance, and poor efficacy in advanced or metastatic dis- | instability and intra- and inter-tumor heterogeneity, drives drug resistance, treatment failure, and tumor progression [5] |\n| ease. These limitations have driven the rapid development of |  |\n| cancer immunotherapy, which stimulates or modulates the | Traditional preclinical models often fail to reflect the immu- |\n| patient's immune system to recognize and attack cancer cells | nobiological characteristics of human cancer accurately. For |\n| Zhen Wang and Peipei Yin authors contributed equally","cbCailTv1uInAzes","https://ap.wps.com/l/cbCailTv1uInAzes","pdf",1268246,17,"English","# Abstract\n# Introduction","[{\"question\":\"Why are preclinical testing platforms important for immunotherapy research?\",\"answer\":\"Robust preclinical platforms are needed because immunotherapy progress is slowed by limitations in accurately evaluating treatments before clinical use.\"},{\"question\":\"What advantages do tumor organoids offer compared with conventional models?\",\"answer\":\"Tumor organoids better reflect histological, genetic, and phenotypic features of native tumors and can partially model the tumor microenvironment.\"},{\"question\":\"How can organoid models incorporate tumor microenvironment components?\",\"answer\":\"By integrating immune cells, vascular-associated components, and cancer-associated fibroblasts, complex organoid systems can recapitulate aspects of the tumor microenvironment.\"}]","Harnessing Tumor Organoids to Revolutionize Immunotherapy Research | PDF",1790087359,43,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79de4e5bb9952e717274db57a068834f.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f46f1b684fae26f4cb2ce0d92bab22c7.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/496b19575258cd66f7fd4cb6210e52d7.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6306f80dd11d6168ad8f44c544a1c69b.webp",980,1287]